Axonics (Axonics) Total Liabilities

: $82.4 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Axonics's Total Liabilities for the quarter that ended in Dec. 2023 was $82.4 Mil.

Axonics's quarterly Total Liabilities increased from Jun. 2023 ($48.46 Mil) to Sep. 2023 ($50.13 Mil) and increased from Sep. 2023 ($50.13 Mil) to Dec. 2023 ($82.36 Mil).

Axonics's annual Total Liabilities increased from Dec. 2021 ($65.51 Mil) to Dec. 2022 ($89.21 Mil) but then declined from Dec. 2022 ($89.21 Mil) to Dec. 2023 ($82.36 Mil).

Axonics Total Liabilities Historical Data

The historical data trend for Axonics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

36.82

54.84

65.51

89.21

82.36

Axonics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities																89.21	89.09	48.46	50.13	82.36

Axonics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Axonics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45.816	+	(25.84	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.703	+	0)
	=	82.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	719.923	-	637.564
	=	82.4

Axonics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45.816	+	(25.84	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.703	+	0)
	=	82.4

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	719.923	-	637.564
	=	82.4

Axonics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Axonics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (Axonics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

0I3:Germany 0I3:Germany

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Executives

Karen Noblett	officer: Chief Medical Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese	officer: Chief Financial Officer	15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen	officer: See Remarks	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr	officer: Chief Commercial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama	officer: Chief Operating Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock	officer: Chief Marketing Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen	director, officer: Chief Executive Officer
Esteban Lopez	director	6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski	director	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara	director	C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms	director, 10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera	10 percent owner	374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski	director, 10 percent owner	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920